EFPIA's disclosure code uncovered

21 December 2015

From June 2016 all pharmaceutical companies in Europe will be required to publish payments made to health care professionals (HCP) or organizations (HCO) under a new disclosure code being introduced by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The over-arching aim of the code is to bring more transparency to the life sciences industry across Europe in a bid to stamp out unethical practices. But will it achieve its objectives?

The Pharma Letter’s Katie Osborne takes an in-depth look at the EFPIA’s code and how it will work in practice:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK